In addition, combining CAR-T therapy with immune checkpoint inhibitors, such as anti-PD-1/PD-L1 antibodies, can lead to synergistic effects via mitigation of T cell exhaustion and enhanced anti-tumor response [302–304]. This evidence concerns the gene CD274 and neoplasm.